Data from more than 100 company-sponsored studies will be featured, including 34 oral presentations, highlighting the range of modalities, targets and research platforms the company is advancing and showcasing our commitment to scientific progress across hematologic diseases.
Key data being presented by Bristol Myers Squibb and its partners at the 2022 ASH annual meeting and Exposition include:
Updated data including longer-term follow up from the primary analysis of the Phase 3 TRANSFORM study evaluating Breyanzi (lisocabtagene maraleucel) versus the standard of care as a second-line treatment in relapsed or refractory large B-cell lymphoma
Updated data from the primary analysis of the Phase 2 OUTREACH study evaluating Breyanzi as a third-line plus treatment in relapsed or refractory LBCL in the community setting
Safety and efficacy results of the match-adjusted indirect comparison of the TRANSFORM versus ZUMA-7 studies evaluating Breyanzi versus axicabtagene ciloleucel in the second-line setting in relapsed or refractory LBCL
Two first disclosures of results from cohorts 2a and 2c of the Phase 2 KarMMa-2 trial evaluating Abecma in high-risk multiple myeloma
First disclosure of preliminary Phase 1 results for GPRC5D chimeric antigen receptor T cell therapy in patients with relapsed/refractory multiple myeloma, including patients previously treated with a B-cell maturation antigen -directed CAR T cell therapy
Multiple analyses of Reblozyl (luspatercept-aamt), including overall survival data from the Phase 3 MEDALIST study in lower-risk myelodysplastic syndromes and real-world, longer-term results from the Phase 2 BEYOND study in beta thalassemia
Multiple analyses of Inrebic (fedratinib), including the primary analysis of safety and efficacy from the Phase 3b FREEDOM trial in intermediate- or high-risk myelofibrosis
Longitudinal analyses of acute myeloid leukemia gene mutations with Onureg (azacitidine tablets) from the Phase 3 QUAZAR AML-001 study
First disclosure of preliminary results from the dose escalation and expansion components of the Phase 1 CC-93269 MM-001 study, evaluating subcutaneous bispecific T cell engager alnuctamab in heavily pretreated multiple myeloma
First results from dose expansion cohort of the CC-92480 Phase 1/2 MM-001 study, evaluating CELMoDTM agent mezigdomide with dexamethasone in patients with R/R multiple myeloma
Results from post-BCMA cohort of the CC-220 Phase 1/2 MM-001 study, evaluating CELMoD agent iberdomide with dexamethasone in patients with R/R multiple myeloma previously treated with a BCMA-directed therapy
First results from a Phase 1/2 study evaluating BMS-986158, a potent Bromodomain and Extraterminal inhibitor, as monotherapy and in combination with ruxolitinib or Inrebic in intermediate- or high-risk myelofibrosis
To learn more about our science and commitment in hematology, check out the BMS at ASH 2022 content hub. You can find additional information about BMS' presence at the meeting on the ASH website.
Bristol Myers Squibb is inspired by a single vision -- transforming patients' lives through science. The goal of the company's cancer research is to deliver medicines that offer each patient a better, healthier life and to make cure a possibility.
Building on a legacy across a broad range of cancers that have changed survival expectations for many, Bristol Myers Squibb researchers are exploring new frontiers in personalized medicine, and through innovative digital platforms, are turning data into insights that sharpen their focus.
Deep scientific expertise, cutting-edge capabilities and discovery platforms enable the company to look at cancer from every angle. Cancer can have a relentless grasp on many parts of a patient's life, and Bristol Myers Squibb is committed to taking actions to address all aspects of care, from diagnosis to survivorship.
Because as a leader in cancer care, Bristol Myers Squibb is working to empower all people with cancer to have a better future.
Breyanzi is a CD-19 directed chimeric antigen receptor T cell therapy, administered as a defined composition to reduce variability of the CD8 and CD4 component dose.
Breyanzi has a 4-1BB costimulatory domain which enhances the expansion and persistence of the CAR T cells.
Breyanzi was previously approved by the US Food and Drug Administration for the treatment of adult patients with relapsed or refractory LBCL after two or more lines of systemic therapy, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B.
Breyanzi is available only through a restricted program under a Risk Evaluation and Mitigation Strategy called the BREYANZI REMS.
Breyanzi is also approved in Europe, Switzerland, Canada and Japan for relapsed and refractory LBCL after two or more lines of systemic therapy. Bristol Myers Squibb's clinical development program for Breyanzi includes clinical studies in earlier lines of treatment for patients with relapsed or refractory LBCL and other types of lymphoma.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886